Introduction to MHE Animal Models

The minimal hepatic encephalopathy (MHE) animal model is an experimental system designed to mimic the subclinical neurocognitive impairments associated with early-stage liver dysfunction. It is typically established by inducing chronic liver injury—such as with carbon tetrachloride (CCl₄) or bile duct ligation—or by employing models of ammonia metabolism dysregulation. Animals in this model generally do not exhibit overt severe neurological symptoms like coma, yet they may display impaired learning and memory, reduced attention, and mild deficits in motor coordination. Concurrently, they show pathological features such as elevated blood ammonia levels, altered astrocytic function, and disrupted cerebral energy metabolism. This model is widely used for investigating the early pathogenic mechanisms of hepatic encephalopathy and for screening potential therapeutic interventions.

Service Advantages of Aniphe BioLab’s MHE Animal Model Platform

The Aniphe BioLab mild hepatic encephalopathy (MHE) animal model platform, centered on robust liver injury induction and precise early-stage neurocognitive assessment, provides a reliable in vivo modeling system for investigating the mechanisms of hepatic encephalopathy and evaluating therapeutic interventions.

	Multiple modeling methods are well-established. It encompasses classic modeling approaches such as bile duct ligation (BDL) and ammonia metabolism disorders, catering to diverse research needs.
	Liver function impairment is stable and well-controlled. Serum ammonia levels and changes in liver function indices show high consistency, and the model demonstrates good reproducibility.
	High pathological consistency of the brain–liver axis It enables the simultaneous observation of key alterations, including astrocyte dysfunction, neuroinflammation, and disturbances in cerebral energy metabolism.
	Multidimensional Behavioral Assessment By integrating maze-based experiments, cognitive tasks, and motor coordination assessments, we can achieve a refined early-stage evaluation of neurological function.
	Supports multi‑time‑window studies It covers both the progressive stages of liver injury and the early phase of minimal hepatic encephalopathy, aligning with studies on dynamic mechanisms.

Modeling cycle	4–14 weeks
Laboratory animals	Adult male SD rats or Wistar rats
Positive drug	Lactulose (an intestinal ammonia‑absorption inhibitor), rifaximin (a non‑absorbable intestinal antibiotic), ornithine aspartate (LOLA, which promotes ammonia metabolism), branched‑chain amino acids (BCAAs), and sodium benzoate/sodium phenylacetate (which facilitate ammonia excretion) are commonly used as positive controls.
Application areas	Pathogenesis of MHE (synergistic effects of hyperammonemia and neuroinflammation, oxidative stress, and impaired cerebral energy metabolism); screening of novel ammonia‑lowering or neuroprotective agents; investigation of the gut–liver–brain axis regulatory mechanisms; validation of early biomarkers; and exploration of intervention strategies for cirrhosis‑associated mild cognitive impairment.

Construction of MHE animal models

01 Thioacetamide (TAA)-induced method: Chronic or intermittent administration induces progressive hepatocellular injury and fibrosis, leading to impaired liver function and elevated blood ammonia levels, which in turn can result in mild cognitive impairment.

02 Bile Duct Ligation (BDL) Method: This surgical procedure obstructs bile flow, inducing cholestatic liver injury and chronic liver failure, accompanied by metabolic disturbances and the accumulation of neurotoxic substances.

Both models can stably exhibit the typical phenotypes of MHE—namely, impaired learning and memory, reduced exploratory behavior, and mild motor coordination deficits—even in the absence of overt coma.